BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada

  June 18, 2026

   · 

  6 min read
• 

  Approvals

  GSK, Spero’s oral antibiotic wins first FDA nod for complicated UTI

  After being rejected in June 2022, GSK paid Spero Therapeutics $66 million for an exclusive worldwide license to develop and commercialize the drug. It’s the second oral antibiotic GSK has brought to market since the beginning of last year.

  June 18, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Biogen makes up to $1B immuno play with RayThera takeover

  RayThera will bring three preclinical assets into the Biogen fold, all with anti-inflammatory activity. The most mature of these assets is expected to enter Phase 1 development in Q3.

  June 18, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pancreatic cancer

  Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution

  Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.

  June 18, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• Press Releases

  Alturos Therapeutics advancement of lead candidate ALT0135, a potentially first-in-class, orally bioavailable small molecule, into IND-enabling studies

  June 18, 2026

   · 

  1 min read
• Press Releases

  Amplio Spine Acquires and Commercializes KeyLift®, an FDA-Cleared Expandable Interlaminar Stabilization System Indicated for Supplemental Fusion of the Non-Cervical Spine

  June 18, 2026

   · 

  5 min read
• Press Releases

  U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

  June 18, 2026

   · 

  11 min read
• Press Releases

  Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

  June 18, 2026

   · 

  1 min read
• Press Releases

  Pfizer Announces Chief Financial Officer Transition

  June 18, 2026

   · 

  4 min read
• Press Releases

  Essential Pharma appoints Becki Morison as Chief Executive Officer

  June 18, 2026

   · 

  3 min read